Endothelin‐1 (ET‐1) is known to contribute to the renal hypertension observed following treatment with calcineurin inhibitors such as CsA (Perico et al. 1990; Lanese and Conger 1993; Textor et al. 1995; Cavarape et al. 1998), and previous studies in rats have demonstrated ET‐1 plays a role in CsA‐induced hypertension (Takeda et al. 1995). Here, EDN1 is linked to hypertensive disorder.